METTL3-mediated m⁶A modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p/MDR1 axis

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: gLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–17. DOI:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int. 2021;21(1):213.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Hajimazdarany S, Mohan CD, et al. Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: tumorigenesis, chemoresistance, and radioresistance. Pharmacol Res. 2022;186:106535.
   PubMed Web of Science ®Google Scholar
• He J, Zhu S, Liang X, et al. LncRNA as a multifunctional regulator in cancer multi-drug resistance. Mol Biol Rep. 2021;48(8):1–15. DOI:10.1007/s11033-021-06603-7
   PubMed Web of Science ®Google Scholar
• He S, Feng Y, Zou W, et al. The Role of the SOX9/lncRNA ANXA2P2/miR-361-3p/SOX9 Regulatory Loop in Cervical Cancer Cell Growth and Resistance to Cisplatin. Front Oncol. 2021;11:784525.
   PubMed Web of Science ®Google Scholar
• Yuan F, Lou Z, Zhou Z, et al. Long non‑coding RNA KCNQ1OT1 promotes nasopharyngeal carcinoma cell cisplatin resistance via the miR‑454/USP47 axis. Int J Mol Med. 2021;47(4).
   Web of Science ®Google Scholar
• Ren Z, Xu Y, Wang X, et al. KCNQ1OT1 affects cell proliferation, invasion, and migration through a miR-34a/Notch3 axis in breast cancer. Environ Sci Pollut Res Int. 2022;29(19):28480–28494. DOI:10.1007/s11356-021-18434-x
   PubMed Web of Science ®Google Scholar
• Wu Y, Bi Q-J, Han R, et al. Long noncoding RNA KCNQ1OT1 is correlated with human breast cancer cell development through inverse regulation of hsa-miR-107. Biochem Cell Biol. 2020;98(3):338–344. DOI:10.1139/bcb-2019-0271
   PubMedGoogle Scholar
• Zhang N, Zuo Y, Peng Y, et al. Function of N6-Methyladenosine Modification in Tumors. J Oncol. 2021;2021:6461552.
   PubMed Web of Science ®Google Scholar
• Zhao C, Ling X, Xia Y, et al. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis. Cancer Cell Int. 2021; 21(1): 441. DOI:10.1186/s12935-021-02113-5
   Google Scholar
• Li S, Jiang F, Chen F, et al. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer. J Biochem Mol Toxicol. 2022;36(1):e22922. DOI:10.1002/jbt.22922
   PubMed Web of Science ®Google Scholar
• López-Urrutia E, Bustamante Montes LP, Ladrón de Guevara Cervantes D, et al. Crosstalk Between Long Non-coding RNAs, Micro-RNAs and mRnas: deciphering Molecular Mechanisms of Master Regulators in Cancer. Front Oncol. 2019;9:669.
   PubMed Web of Science ®Google Scholar
• Heydarzadeh S, Ranjbar M, Karimi F, et al. Overview of host miRNA properties and their association with epigenetics, long non-coding RNAs, and Xeno-infectious factors. Cell Biosci. 2021;11(1):43. DOI:10.1186/s13578-021-00552-1
   PubMed Web of Science ®Google Scholar
• Liu H, Bian Q-Z, Zhang W, et al. Circulating microRna‑103a‑3p could be a diagnostic and prognostic biomarker for breast cancer. Oncol Lett. 2022;23(1):38. DOI:10.3892/ol.2021.13156
   PubMed Web of Science ®Google Scholar
• Liu X, Qiao K, Zhu K, et al. Long Noncoding RNA HCG18 Promotes Malignant Phenotypes of Breast Cancer Cells via the HCG18/miR-103a-3p/UBE2O/mTORC1/HIF-1α–Positive Feedback Loop. Front Cell Dev Biol. 2021;9:675082.
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang J, Yang S. MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1. Exp Ther Med. 2020;19(3):1797–1805.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang H, Li Z, et al. Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. Br J Cancer. 2018;119(2):182–192. DOI:10.1038/s41416-018-0119-5
   PubMed Web of Science ®Google Scholar
• Elia SG, Al‐karmalawy AA, Nasr MY, et al. Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: in vitro and molecular docking study. J Biochem Mol Toxicol. 2022;36(1):e22938. DOI:10.1002/jbt.22938
   PubMed Web of Science ®Google Scholar
• Wang Q, Liang D, Shen P, et al. Hsa_circ_0092276 promotes doxorubicin resistance in breast cancer cells by regulating autophagy via miR-348/ATG7 axis. Transl Oncol. 2021;14(8):101045. DOI:10.1016/j.tranon.2021.101045
   PubMed Web of Science ®Google Scholar
• Yi YC, Chen X-Y, Zhang J, et al. Novel insights into the interplay between m(6)A modification and noncoding RNAs in cancer. Mol Cancer. 2020;19(1):121. DOI:10.1186/s12943-020-01233-2
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Brown JS. The Evolution and Ecology of Resistance in Cancer Therapy. Cold Spring Harb Perspect Med. 2020;10(11):10(11.
   Web of Science ®Google Scholar
• McGuirk S, Audet-Delage Y, Annis MG, et al. Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. Elife. 2021;10:10.
   Google Scholar
• Zhang X, Xie K, Zhou H, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19(1):47. DOI:10.1186/s12943-020-01171-z
   PubMed Web of Science ®Google Scholar
• Si X, Zhang G, Li M, et al. LncRNA DDX11-AS1 Promotes Chemoresistance through LIN28A-Mediated ATG12 mRNA Stabilization in Breast Cancer. Pharmacology. 2023;108(1):61–73. DOI:10.1159/000527222
   PubMed Web of Science ®Google Scholar
• Sun H, Sun Y, Chen Q, et al. LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p. Life Sci. 2020;241:117161.
   PubMed Web of Science ®Google Scholar
• Wang W, Han S, Gao W, et al. Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 from miR-761. Cell Mol Neurobiol. 2022;42(3):695–708. DOI:10.1007/s10571-020-00958-4
   PubMed Web of Science ®Google Scholar
• Shriwas O, Mohapatra P, Mohanty S, et al. The Impact of m6A RNA Modification in Therapy Resistance of Cancer: implication in Chemotherapy, Radiotherapy, and Immunotherapy. Front Oncol. 2020;10:612337.
   PubMed Web of Science ®Google Scholar
• Jin D, Guo J, Wu Y, et al. M(6)a mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12(1):135. DOI:10.1186/s13045-019-0830-6
   PubMed Web of Science ®Google Scholar
• Ban Y, Tan P, Cai J, et al. LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol. 2020;14(6):1282–1296. DOI:10.1002/1878-0261.12676
   PubMed Web of Science ®Google Scholar
• Li M, Xia M, Zhang Z, et al. METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma. Int J Oncol. 2022;61(3).
   Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(D1):D92–7. DOI:10.1093/nar/gkt1248
   PubMed Web of Science ®Google Scholar
• Zhu L, Wang F, Fan W, et al. lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis. Acta Biochim Biophys Sin. 2021;53(9):1198–1206. DOI:10.1093/abbs/gmab098
   Google Scholar
• Sun Z, Zhang Q, Yuan W, et al. MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis. J Exp Clin Cancer Res. 2020;39(1):250. DOI:10.1186/s13046-020-01705-9
   PubMed Web of Science ®Google Scholar
• Santos SA, Paulo A. Small molecule inhibitors of multidrug resistance gene (MDR1) expression: preclinical evaluation and mechanisms of action. Curr Cancer Drug Targets. 2013;13(8):814–828.
   PubMed Web of Science ®Google Scholar
• Yi D, Xu L, Wang R, et al. MiR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int. 2019;43(1):12–21. DOI:10.1002/cbin.11071
   PubMed Web of Science ®Google Scholar